MCKESSON CORPORATION

(MCK)
  Report
Delayed Nyse  -  04:04 2022-07-01 pm EDT
329.53 USD   +1.02%
06/29McKesson Corporation Announces First Quarter Fiscal 2023 Earnings Release Date
BU
06/27The Oncology Institute, McKesson Expand Drug Distribution Collaboration
MT
06/27The Oncology Institute Announces Expanded Strategic Agreement with McKesson for Distribution of Pharmaceuticals
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
326.24(c) 321.55(c) 328.06(c) 326.21(c) 329.53(c) Last
921 756 852 767 1 080 472 1 215 856 826 566 Volume
+1.46% -1.44% +2.02% -0.56% +1.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 268 B - -
Net income 2023 2 858 M - -
Net Debt 2023 978 M - -
P/E ratio 2023 16,9x
Yield 2023 0,59%
Sales 2024 275 B - -
Net income 2024 2 854 M - -
Net Debt 2024 264 M - -
P/E ratio 2024 16,2x
Yield 2024 0,62%
Capitalization 47 314 M 47 314 M -
EV / Sales 2023 0,18x
EV / Sales 2024 0,17x
Nbr of Employees 66 500
Free-Float 52,4%
More Financials
Company
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows: - distribution of pharmaceutical products (94.6%); - distribution of medical and surgical products (4.2%); - other (1.2%): primarily technology services and software sales. The United States accounts for 84.9% of net sales. 
Sector
Drug Retailers
Calendar
07/22 | 09:30amShareholder meeting
More about the company
Ratings of McKesson Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about MCKESSON CORPORATION
06/29McKesson Corporation Announces First Quarter Fiscal 2023 Earnings Release Date
BU
06/27The Oncology Institute, McKesson Expand Drug Distribution Collaboration
MT
06/27The Oncology Institute Announces Expanded Strategic Agreement with McKesson for Distrib..
CI
06/24MCKESSON CORPORATION(NYSE : MCK) added to Russell Top 200 Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) added to Russell 1000 Growth-Defensive Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) dropped from Russell Midcap Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) added to Russell 1000 Value-Defensive Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) added to Russell Top 200 Value Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) added to Russell Top 200 Growth Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) dropped from Russell Midcap Growth Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) dropped from Russell Midcap Value Index
CI
06/24MCKESSON CORPORATION(NYSE : MCK) added to Russell 1000 Defensive Index
CI
06/23HCA Healthcare, McKesson to Establish Oncology Research Joint Venture
MT
06/23McKesson and HCA Healthcare Announce Plans to Form an Oncology Research Joint Venture t..
AQ
06/23McKesson and HCA Healthcare Announce Plans to Form an Oncology Research Joint Venture t..
BU
More news
News in other languages on MCKESSON CORPORATION
06/27L'Institut d'Oncologie annonce une entente stratégique élargie avec McKesson pour la di..
06/24EN DIRECTO DESDE LOS MERCADOS : Indra, Alphabet, Leonardo, Fedex, Zalando, Mercedes, Atlan..
06/24BOLSA DE MADRID : Dos por docena
06/24Deux à la douzaine
06/24EN DIRECT DES MARCHES : Stellantis, Sanofi, Capgemini, GTT, Fedex, Zalando, Mercedes, Atla..
More news
Analyst Recommendations on MCKESSON CORPORATION
More recommendations
Stock Trading Strategies
MCKESSON CORPORATION - 03/28
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart MCKESSON CORPORATION
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 329,53 $
Average target price 362,31 $
Spread / Average Target 9,95%
EPS Revisions
Managers and Directors
Brian Scott Tyler Chief Executive Officer & Director
Britt J. Vitalone Chief Financial Officer & Executive Vice President
Donald R. Knauss Independent Chairman
Nancy Flores Chief Technology & Information Officer, EVP
Maria Teresa Lensing Chief Technology Officer-Engineering & SVP